Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darigabat - Cerevel Therapeutics

Drug Profile

Darigabat - Cerevel Therapeutics

Alternative Names: CVL-865; PF-06372865; PF-6372865

Latest Information Update: 03 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics; Pfizer
  • Class Analgesics; Antiepileptic drugs; Anxiolytics; Fluorobenzenes; Heterocyclic compounds; Imidazoles; Phenyl ethers; Pyrazines; Small molecules; Sulfones
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy; Panic disorder; Seizures
  • Preclinical Anxiety disorders
  • Discontinued Back pain; Generalised anxiety disorder

Most Recent Events

  • 30 May 2024 Cerevel Therapeutics plans a phase I pharmacokinetics trial for Neurological disorders (In Volunteers) in the US (PO, capsule)(NCT06435923)
  • 31 Jul 2023 Phase-II clinical trials in Panic disorder in USA (PO) (NCT05941442)
  • 07 Jul 2023 Cerevel Therapeutics completes a phase I pharmacokinetics trial (In volunteers, In adults) in USA (PO,Tablet) (NCT05824143)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top